Expression and significance of HSP90 in plasma of patients with multiple myeloma.
10.7534/j.issn.1009-2137.2014.05.027
- Author:
Bin-Bin ZOU
1
;
Ning-Hong GUO
1
;
Qing-Zhi SHI
2
;
Jian-Yuan HUA
1
;
Zhen-Jiang LI
1
;
Wen-Feng HE
1
;
Yuan SONG
1
Author Information
1. Department of Hematology, The Second Affiliated Hospital,Nanchang University, Nanchang 330006,Jiangxi Province, China.
2. Department of Hematology, The Second Affiliated Hospital,Nanchang University, Nanchang 330006,Jiangxi Province, China. E-mail: qingzhis@sohu.com.
- Publication Type:Journal Article
- MeSH:
HSP90 Heat-Shock Proteins;
blood;
Humans;
Multiple Myeloma;
blood;
Myeloma Proteins;
Prognosis
- From:
Journal of Experimental Hematology
2014;22(5):1326-1330
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the expression of heat shock protein 90 (HSP90) in peripheral blood plasma of patients with multipl myeloma (MM), and to explore its possible role in the pathogenesis of MM, and its relationship with treatment, prognosis and the outcome of patients. The peripheral blood samples from 58 patients with MM and 20 healthy volunteers were collected. The plasma concentration of HSP90 in patients and healthy volunteers was measured by ELISA. The results showed that the concentration of HSP90 in peripheral blood of patients with MM was significantly higher than that in the healthy volunteers [(32.398 ± 3.674) vs (25.762 ± 2.916) ng/ml] (P < 0.001). The concentration of HSP90 showed positively correlation with International Staging System(ISS) stage, therapeutic response, frequency of plasmocyte, globulin, immune globulin, M-protein, β2 micro-globulin, and light chain of MM patients (P < 0.05) ; while it showed little correlation with sex, age and type of MM patients (P > 0.05) . It is concluded that the HSP90 may be involved in the occurrence and development of MM. Detection of HSP90 in plasma would contribute to judge the clinical course, therapeutic efficacy and prognosis of MM patients.
